186 related articles for article (PubMed ID: 36923216)
1. Eugenol modulates the NOD1-NF-κB signaling pathway
Shi X; Zhang W; Bao X; Liu X; Yang M; Yin C
Front Endocrinol (Lausanne); 2023; 14():1136067. PubMed ID: 36923216
[TBL] [Abstract][Full Text] [Related]
2. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
Velloso FJ; Campos AR; Sogayar MC; Correa RG
BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
[TBL] [Abstract][Full Text] [Related]
3. SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer.
Chan SH; Kuo WH; Wang LH
J Biomed Sci; 2023 Nov; 30(1):93. PubMed ID: 38037106
[TBL] [Abstract][Full Text] [Related]
4. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription.
Yang W; Li J; Zhang M; Yu H; Zhuang Y; Zhao L; Ren L; Gong J; Bi H; Zeng L; Xue Y; Yang J; Zhao Y; Wang S; Gao S; Fu Z; Li D; Zhang J; Wang T; Shan M; Tang B; Li X
J Exp Clin Cancer Res; 2022 Feb; 41(1):67. PubMed ID: 35180863
[TBL] [Abstract][Full Text] [Related]
7. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
8. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
9. Inhibited Expression of NLRP12 Promotes the Development of Triple-Negative Breast Cancer by Activating the NF-κB Pathway.
Kuang W; Gu Q; Zhou Y; Xiao X; He D; Deng Q
Cell Biochem Biophys; 2023 Dec; 81(4):727-735. PubMed ID: 37658975
[TBL] [Abstract][Full Text] [Related]
10. IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
House CD; Grajales V; Ozaki M; Jordan E; Wubneh H; Kimble DC; James JM; Kim MK; Annunziata CM
BMC Cancer; 2018 May; 18(1):595. PubMed ID: 29801480
[TBL] [Abstract][Full Text] [Related]
11. GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway.
Li C; Geng C
Biol Pharm Bull; 2023; 46(2):209-218. PubMed ID: 36724950
[TBL] [Abstract][Full Text] [Related]
12. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
[TBL] [Abstract][Full Text] [Related]
13. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
[TBL] [Abstract][Full Text] [Related]
14. Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.
Jeon M; Han J; Nam SJ; Lee JE; Kim S
Chem Biol Interact; 2016 Oct; 258():126-33. PubMed ID: 27567548
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
Huang P; Ouyang DJ; Chang S; Li MY; Li L; Li QY; Zeng R; Zou QY; Su J; Zhao P; Pei L; Yi WJ
Cell Commun Signal; 2018 Nov; 16(1):92. PubMed ID: 30497491
[TBL] [Abstract][Full Text] [Related]
16. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway.
Dai X; Hou Y; Deng T; Lin G; Cao Y; Yu G; Wei W; Zheng Q; Huang L; Ma S
Eur J Pharmacol; 2023 Sep; 954():175861. PubMed ID: 37380046
[TBL] [Abstract][Full Text] [Related]
17. Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.
Provance OK; Geanes ES; Lui AJ; Roy A; Holloran SM; Gunewardena S; Hagan CR; Weir S; Lewis-Wambi J
Cancer Lett; 2021 Aug; 514():12-29. PubMed ID: 34022283
[TBL] [Abstract][Full Text] [Related]
18. Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity.
Gao L; Chen S; Hong M; Zhou W; Wang B; Qiu J; Xia J; Zhao P; Fu L; Wang J; Dai Y; Xie N; Yang Q; Huang HD; Gao X; Zou C
Signal Transduct Target Ther; 2021 Jul; 6(1):250. PubMed ID: 34219129
[TBL] [Abstract][Full Text] [Related]
19. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
Zhang M; Meng M; Liu Y; Qi J; Zhao Z; Qiao Y; Hu Y; Lu W; Zhou Z; Xu P; Zhou Q
Breast Cancer Res; 2021 Dec; 23(1):116. PubMed ID: 34922602
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/CXCR4 signaling axis in preclinical breast cancer model.
Gupta N; Mohan CD; Shanmugam MK; Jung YY; Chinnathambi A; Alharbi SA; Ashrafizadeh M; Mahale M; Bender A; Kumar AP; Putti TC; Rangappa KS; Zhang X; Ahn KS; Sethi G
Environ Res; 2023 Sep; 232():116335. PubMed ID: 37290620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
